A 52-Week, Open-Label, Long-Term Safety Study of LY2189265 in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase III
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Dulaglutide (Primary) ; Alpha-glucosidase inhibitors; Biguanides; Insulinotropin agonists; Sulfonylureas; Thiazolidinediones
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 27 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.